Clinical Trial Update: A Multiple-Dose Study to Evaluate MK-1075 in Hepatitis C Virus (HCV) Infected Participants (MK-1075-004) [Phase 1]

View source ↗

Summary

Phase 1 multiple-dose study assessing MK-1075 in participants infected with hepatitis C virus has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• MK-1075

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C Virus Infection | Phase 1 | Status: COMPLETED | Results posted: 2018-11-13